Literature DB >> 2193096

Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor.

D H Munn1, N K Cheung.   

Abstract

Macrophages and cultured human monocytes can mediate efficient antibody-dependent cytotoxicity (ADCC) against human tumor cells using monoclonal antibodies (mAbs). The mechanism of this killing is usually assumed to involve secreted factors (reactive oxygen intermediates, tumor necrosis factor, or other cytotoxic factors) leading to target cell lysis. In this study, we present evidence that phagocytosis of intact target cells is the principal mechanism of antitumor cytotoxicity in our in vitro model of ADCC by cultured monocytes. Human monocytes cultured in recombinant human macrophage colony-stimulating factor ingested up to 100% of fluorochrome-labeled melanoma and neuroblastoma target cells, in the presence of an appropriate antitumor mAb. Electron microscopy demonstrated phagocytosis of intact tumor cells by cultured monocytes during ADCC. All of the radionuclide in radiolabeled target cells was taken up by monocytes during phagocytosis. By preventing the release of radioisotope tracers, phagocytosis thus prevents the detection of this very efficient form of cytotoxicity by most conventional assays.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193096      PMCID: PMC2188164          DOI: 10.1084/jem.172.1.231

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  THE PHAGOCYTOSIS OF TUMOR CELLS IN VITRO.

Authors:  B BENNETT; L J OLD; E A BOYSE
Journal:  Transplantation       Date:  1964-03       Impact factor: 4.939

2.  Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.

Authors:  C S Woodhouse; A C Morgan
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration of tumor cells.

Authors:  R G Kilbourn; J Klostergaard; G Lopez-Berestein
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

5.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

Authors:  N K Cheung; U M Saarinen; J E Neely; B Landmeier; D Donovan; P F Coccia
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

6.  Antibody-dependent cytolysis (ADCC) of tumor cells by activated murine macrophages is a two-step process: quantification of target binding and subsequent target lysis.

Authors:  W J Johnson; D P Bolognesi; D O Adams
Journal:  Cell Immunol       Date:  1984-01       Impact factor: 4.868

7.  Human serum induces maturation of human monocytes in vitro. Changes in cytolytic activity, intracellular lysosomal enzymes, and nonspecific esterase activity.

Authors:  R A Musson
Journal:  Am J Pathol       Date:  1983-06       Impact factor: 4.307

8.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

Authors:  B M Mueller; C A Romerdahl; S D Gillies; R A Reisfeld
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

9.  Monocyte and granulocyte-mediated tumor cell destruction. A role for the hydrogen peroxide-myeloperoxidase-chloride system.

Authors:  S J Weiss; A Slivka
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

10.  Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays.

Authors:  D H Munn; N K Cheung
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  28 in total

1.  Breast Cancer: A Revolutionary Concept.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  Phenotypic and functional characterization of a new human macrophage cell line K1m demonstrating immunophagocytic activity and signalling through HLA class II.

Authors:  D P Dialynas; M J Lee; L E Shao; P C Tan; J Yu
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 3.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 4.  Impact of the immune system and immunotherapy in colorectal cancer.

Authors:  Janet L Markman; Stephen L Shiao
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 5.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 6.  Monoclonal antibody-based therapy for neuroblastoma.

Authors:  N K Cheung
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 7.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

8.  Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor.

Authors:  D H Munn; N K Cheung
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

Review 9.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 10.  T cell receptor mimic antibodies for cancer therapy.

Authors:  Leonid Dubrovsky; Tao Dao; Ron S Gejman; Elliott J Brea; Aaron Y Chang; Claire Y Oh; Emily Casey; Dmitry Pankov; David A Scheinberg
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.